Loading...
XSHG600285
Market cap1.69bUSD
Dec 23, Last price  
22.17CNY
1D
-3.06%
1Q
13.23%
Jan 2017
73.75%
Name

Henan Lingrui Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600285 chart
P/E
21.70
P/S
3.72
EPS
1.02
Div Yield, %
2.79%
Shrs. gr., 5y
-0.83%
Rev. gr., 5y
10.03%
Revenues
3.31b
+10.31%
340,046,509399,374,464392,177,875520,330,937423,244,212463,281,143381,238,790448,778,162562,700,777686,974,842826,274,1171,070,767,1931,439,313,4721,848,525,0852,053,113,1802,157,052,0012,331,577,4462,693,510,9183,001,862,2133,311,472,606
Net income
568m
+22.09%
15,336,46218,465,89411,119,99569,496,69310,476,57429,314,87748,557,68129,851,40542,453,610105,367,05876,170,879132,477,475345,772,174217,112,186243,263,838294,436,954325,489,250361,542,665465,304,594568,109,302
CFO
813m
-2.57%
35,511,22633,428,27026,763,98715,985,21643,720,671132,607,233040,487,86015,434,351127,269,669124,320,875156,818,48163,262,545105,972,634436,248,604450,154,297450,529,975845,686,168834,909,734813,428,748
Dividend
Jun 20, 20240.8 CNY/sh
Earnings
May 20, 2025

Profile

Henan Lingrui Pharmaceutical Co., Ltd. produces and sells medicines in China. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, tinctures, etc. covering approximately 100 product varieties. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, Shenqi Hypoglycemic capsules, and others. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is based in Xinyang, China.
URL
http://www.lingrui.com/
IPO date
Oct 18, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,311,473
10.31%
3,001,862
11.45%
2,693,511
15.52%
Cost of revenue
2,363,744
2,441,672
2,126,741
Unusual Expense (Income)
NOPBT
947,729
560,190
566,770
NOPBT Margin
28.62%
18.66%
21.04%
Operating Taxes
84,928
51,703
50,852
Tax Rate
8.96%
9.23%
8.97%
NOPAT
862,800
508,487
515,918
Net income
568,109
22.09%
465,305
28.70%
361,543
11.08%
Dividends
(344,285)
(282,126)
(220,644)
Dividend yield
3.55%
3.81%
2.46%
Proceeds from repurchase of equity
(787)
BB yield
0.01%
Debt
Debt current
141,221
95,030
127,988
Long-term debt
13,924
12,394
15,807
Deferred revenue
39,784
38,553
42,779
Other long-term liabilities
1
1
1
Net debt
(1,681,039)
(1,420,390)
(1,022,149)
Cash flow
Cash from operating activities
813,429
834,910
845,686
CAPEX
(21,198)
Cash from investing activities
(243,007)
Cash from financing activities
(272,734)
FCF
921,755
534,647
593,759
Balance
Cash
1,499,101
1,329,717
1,081,437
Long term investments
337,083
198,097
84,507
Excess cash
1,670,610
1,377,720
1,031,268
Stockholders' equity
2,185,042
2,363,285
2,154,787
Invested Capital
1,316,054
1,224,955
1,358,088
ROIC
67.91%
39.37%
38.12%
ROCE
31.45%
21.28%
23.54%
EV
Common stock shares outstanding
566,410
568,170
566,681
Price
17.11
31.21%
13.04
-17.47%
15.80
86.54%
Market cap
9,691,276
30.81%
7,408,930
-17.25%
8,953,564
86.17%
EV
8,017,894
5,996,087
7,939,001
EBITDA
1,025,353
636,440
639,570
EV/EBITDA
7.82
9.42
12.41
Interest
589
775
1,503
Interest/NOPBT
0.06%
0.14%
0.27%